Rep. Jared Moskowitz Purchases Shares of Amgen Inc. (NASDAQ:AMGN)

Representative Jared Moskowitz (D-Florida) recently bought shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on May 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on April 16th. The trade occurred in the Representative's "MORGAN STANLEY ACTIVE ASSETS (5)" account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 4/10/2025.
• Sold $15,001 - $50,000 in shares of The Goldman Sachs Group NYSE: GS on 4/10/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/10/2025.
• Purchased $1,001 - $15,000 in shares of Southern NYSE: SO on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of Sherwin-Williams NYSE: SHW on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 4/7/2025.

Amgen Trading Up 3.6%

AMGN traded up $9.41 during midday trading on Thursday, hitting $271.69. The company's stock had a trading volume of 3,994,633 shares, compared to its average volume of 2,788,265. The firm has a market cap of $146.09 billion, a P/E ratio of 35.99, a PEG ratio of 2.63 and a beta of 0.51. The firm has a 50-day moving average price of $293.04 and a two-hundred day moving average price of $288.89. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.96 earnings per share. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 86.86%.

Analyst Ratings Changes

AMGN has been the subject of several recent research reports. Johnson Rice set a $294.00 target price on Amgen in a report on Wednesday, March 5th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Cantor Fitzgerald initiated coverage on Amgen in a report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective on the stock. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, StockNews.com downgraded Amgen from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $310.23.

Institutional Trading of Amgen

Several large investors have recently made changes to their positions in the business. Wealth Preservation Advisors LLC bought a new position in shares of Amgen in the 1st quarter valued at about $25,000. First Pacific Financial boosted its holdings in shares of Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares during the period. Centricity Wealth Management LLC bought a new position in Amgen during the 4th quarter worth about $25,000. Pinney & Scofield Inc. acquired a new stake in Amgen in the 4th quarter valued at approximately $26,000. Finally, Activest Wealth Management lifted its position in shares of Amgen by 3,433.3% in the first quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after purchasing an additional 103 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.76% of the company's stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida's 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 23rd Congressional District. He declared candidacy for the 2026 election. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor's degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz's career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.